1. Home
  2. CPRI vs NVAX Comparison

CPRI vs NVAX Comparison

Compare CPRI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$15.88

Market Cap

2.4B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.77

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPRI
NVAX
Founded
1981
1987
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
CPRI
NVAX
Price
$15.88
$9.77
Analyst Decision
Buy
Buy
Analyst Count
16
9
Target Price
★ $22.22
$14.22
AVG Volume (30 Days)
2.9M
★ 8.1M
Earning Date
10-30-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
111.40
★ 309.76
EPS
★ 0.60
N/A
Revenue
★ $3,474,000,000.00
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.43
N/A
P/E Ratio
$27.29
★ N/A
Revenue Growth
N/A
★ 64.69
52 Week Low
$12.40
$6.20
52 Week High
$28.27
$13.39

Technical Indicators

Market Signals
Indicator
CPRI
NVAX
Relative Strength Index (RSI) 56.99 40.84
Support Level $14.99 $7.93
Resistance Level $16.05 $10.26
Average True Range (ATR) 0.66 1.10
MACD 0.10 -0.32
Stochastic Oscillator 64.76 5.28

Price Performance

Historical Comparison
CPRI
NVAX

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: